Gadolinium Complexes as MRI Contrast Agents for Diagnosis

Rare Earth Coordination Chemistry: Fundamentals and Applications

Volumn , Issue , 2010, Pages 407-433

  Wong, Wingtak ^a   Chan, Kannie Waiyan ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cancer; Contrast agents; Gadolinium complexes; Liver; Magnetic resonance angiography; Magnetic resonance imaging; Safety

Indexed keywords

EID: 84862111330     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470824870.ch10     Document Type: Chapter

References (159)

1. de Haën, C. (2001) Conception of the first magnetic resonance imaging contrast agents: a brief history. Topics in Magnetic Resonance Imaging, 12, 221-230.
2. Laniado, M., Weinmann, H.J., Schörner, W., et al. (1984) First use of GdDTPA/dimeglumine in man. Physiological Chemistry and Physics and Medical Nuclear Magnetic Resonance, 16, 157-165.
3. Clements, J.P.,Wagner, H.N. Jr, Stern, H.S., andGoodwin, D.A. (1968) Indium 113m diethyltriaminopentacetic acid (DTPA): a new radiopharmaceutical for brain scanning. American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine, 104, 139-144.
4. Runge, V.M. (2008) Notes on "characteristics of gadolinium-DTPAcomplex: a potential NMRcontrast agent''. American Journal of Roentgenology, 190, 1433-1434.
5. Knopp, M.V., Balzer, T., Esser, M., et al. (2006) Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Investigative Radiology, 41, 491-499.
6. Herborn, C.U., Honold, E., Wolf, M., et al. (2007) Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Investigative Radiology, 42, 58-62.
7. Runge, V.M., Dickey, K.M., Williams, N.M., and Peng, X. (2002) Local tissue toxicity in response to extravascular extravasation of magnetic resonance contrast media. Investigative Radiology, 37, 393-398.
8. Laurent, S., Elst, L.V., and Muller, R.N. (2006) Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media and Molecular Imaging, 1, 128-137.
9. Tweedle, M.F. (1992) Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Investigative Radiology, 27, S2-S6.
10. Bellin, M.F. (2006) MR contrast agents, the old and the new. European Journal of Radiology, 60, 314-323.
11. Port, M., Idée, J.M., Medina, C., et al. (2008) Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals, 21, 469-490.
12. Gries, H. and Miklautz, H. (1984) Some physicochemical properties of the gadolinium-DTPA complex, a contrast agent for MRI. Physiological Chemistry and Physics and Medical Nuclear Magnetic Resonance, 16, 105-112.
13. Chang, C.A., Francesconi, L.C., Malley, M.F., et al. (1993) Synthesis, characterization, and crystal structures of M(DO3A) (M=Fe, Gd) and Na[M(DOTA)] (M=Fe, Y, Gd). Inorganic Chemistry, 32, 3501-3508.
14. Caravan, P., Ellison, J.J., McMurry, T.J., and Lauffer, R.B. (1999) Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chemical Reviews, 99, 2293-2352.
15. Solomon, I. (1955) Relaxation processes in a system of two spins. Physical Review, 99, 559-565.
16. Bloembergen, N. (1957) Proton relaxation times in paramagnetic solutions. Journal of Chemical Physics, 27, 572-573.
17. Bloembergen, N. andMorgan, L.O. (1961) Proton relaxation times in paramagnetic solutions effects of electron spin relaxation. Journal of Chemical Physics, 34, 842-850.
18. Lauffer, R.B. (1987) Paramagnetic metal complexes as water proton relaxation agents forNMRimaging: theory and design. Chemical Reviews, 87, 901-927.
19. Chan, K.W.Y. and Wong,W.T. (2007) Small molecular gadolinium(III) complexes as MRI contrast agents for diagnostic imaging. Coordination Chemical Reviews, 251, 2428-2451.
20. Bottrill, M., Kwok, L., and Long, N.J. (2006) Lanthanides in magnetic resonance imaging. Chemical Society Reviews, 35, 557-571.
21. Aime, S., Crich, S.G., Gianolio, E., et al. (2006) High sensitivity lanthanide(III) based probes for MR-medical imaging. Coordination Chemical Reviews, 250, 1562-1579.
22. Xu, J., Franklin, S.J.,Whisenhunt, D.W. Jr, andRaymond, K.N. (1995) Gadolinium complex of tris[(3-hydroxy- 1-methyl-2-oxo-1,2-didehydropyridine-4-carboxamido)ethyl]-amine: a new class of gadolinium magnetic resonance relaxation agents. Journal of the American Chemical Society, 117, 7245-7246.
23. Johnson,A.R., O'Sullivan, B., and Raymond, K.N. (2000) Synthesis of a ligand based upon a new entry into the 3-hydroxy-N-alkyl-2(1H)-pyridinone ring system and thermodynamic evaluation of its gadolinium complex. Inorganic Chemistry, 39, 2652-2660.
24. Xu, J., Churchill, D.G., Botta, M., and Raymond, K.N. (2004) Gadolinium(III) 1,2-hydroxypyridonate-based complexes: toward MRI contrast agents of high relaxivity. Inorganic Chemistry, 43, 5492-5494.
25. Pierre, V.C., Botta, M., Aime, S., and Raymond, K.N. (2006) Tuning the coordination number of hydroxypyridonate-based gadolinium complexes: implications for MRI contrast agents. Journal of the American Chemical Society, 128, 5344-5345.
26. Werner, E.J., Avedano, S., Botta, M., et al. (2007) Highly soluble tris-hydroxypyridonate Gd(III) complexes with increased hydration number, fast water exchange, slow electronic relaxation, and high relaxivity. Journal of the American Chemical Society, 129, 1870-1871.
27. Caravan, P., Amedio, J.C. Jr, Dunham, S.U., et al. (2005) When are two waters worse than one? Doubling the hydration number of a Gd-DTPA derivative decreases relaxivity. Chemistry-A European Journal, 11, 5866-5874.
28. 3+ complexes of interest in magnetic resonance imaging: an integrated and theoretically self-consistent approach. Journal of the American Chemical Society, 118, 9333-9346.
29. Aime, S., Botta, M., Fasano, M., and Terreno, E. (1998) Lanthanide(III) chelates for NMR biomedical applications. Chemical Society Reviews, 27, 19-29.
30. Aime, S., Botta, M., Fasano, M., et al. (1997) Conformational and coordination equilibria on DOTAcomplexes of lanthanide metal ions in aqueous solution studied by 1H-NMR spectroscopy. Inorganic Chemistry, 36, 2059-2068.
31. Aime, S., Barge, A., Botta, M., et al. (1998) Direct NMR spectroscopic observation of a lanthanide-coordinated water molecule whose exchange rate is dependent on the conformation of the complexes. Angewandte Chemie International Edition, 37, 2673-2675.
32. Aime, S., Barge, A., Bruce, J.I., et al. (1999) NMR, relaxometric, and structural studies of the hydration and exchange dynamics of cationic lanthanide complexes of macrocyclic tetraamide ligands. Journal of the American Chemical Society, 121, 5762-5771.
33. 3+: a direct access to water exchange and its role in the isomerization. Journal of the American Chemical Society, 122, 1506-1512.
34. Burai, L., Tóth, E., and Merbach, A.E. (2003) HPLC separation of diastereomers of LnIII-ethylenepropylenetriamine- pentaacetate complexes. Direct assessment of their water exchange rate. Chemical Communications, 2680-2681.
35. Woods, M., Kovacs, Z., Zhang, S., and Sherry, A.D. (2003) Towards the rational design of magnetic resonance imaging contrast agents: isolation of the two coordination isomers of lanthanide DOTA-type complexes. Angewandte Chemie International Edition, 115, 6069-6072.
36. Dunand, F.A., Dickins, R.S., Parker, D., and Merbach, A.E. (2001) Towards rational design of fast waterexchanging Gd(dota-like) contrast agents? Importance of the M/m ratio. Chemistry-A European Journal, 7, 5160-5167.
37. Zhang, S., Kovacs, Z., Burgess, S., et al. (2001) {DOTA-bis(amide)}lanthanide complexes: NMR evidence for differences in water-molecule exchange rates for coordination isomers. Chemistry-A European Journal, 7, 288-296.
38. Lebduškova, P., Hermann, P., Helm, L., et al. (2007) Gadolinium(III) complexes of mono- and diethyl esters of monophosphonic acid analogue of DOTAas potential MRI contrast agents: solution structures and relaxometric studies. Dalton Transactions, 493-501.
39. Ruloff, R., Tóth, É., Scopelliti, R., et al. (2002) Accelerating water exchange for GdIII chelates by steric compression around the water binding site. Chemical Communications, 2630-2631.
40. Terreno, E., Boniforte, P., Botta, M., et al. (2003) The water-exchange rate in neutral heptadentate DO3Alike GdIII complexes: effect of the basicity at the macrocyclic nitrogen site. European Journal of Inorganic Chemistry, 3530-3533.
41. Cohen, S.M., Xu, J., Radkov, E., et al. (2000) Syntheses and relaxation properties of mixed gadolinium hydroxypyridinonate MRI contrast agents. Inorganic Chemistry, 39, 5747-5756.
42. 17O NMR study. Magnetic Resonance in Chemistry, 42, 329-336.
43. Rudovský, J., Botta, M., Hermann, P., et al. (2006) Relaxometric and solution NMR structural studies on ditopic lanthanide(III) complexes of a phosphinate analogue of DOTA with a fast rate of water exchange. Dalton Transactions, 2323-2333.
44. Carrera, C., Digilio, G., Baroni, S., et al. (2007) Synthesis and characterization of a Gd(III) based contrast agent responsive to thiol containing compounds. Dalton Transactions, 4980-4987.
45. Aime, S., Botta, M., Fedeli, F., et al. (2001) High-relaxivity contrast agents for magnetic resonance imaging based on multisite interactions between a β-cyclodextrin oligomer and suitably functionalized GdIII chelates. Chemistry-A European Journal, 7, 5261-5269.
46. Aime, S., Ascenzi, P., Comoglio, E., et al. (1995) Molecular recognition of R- and T-states of human adult hemoglobin by a paramagnetic Gd(II1) complex bymeans of themeasurement of solventwater proton relaxation rate. Journal of the American Chemical Society, 117, 9365-9366.
47. Gløgård, C., Stensrud, G., and Aime, S. (2003) Novel radical-responsive MRI contrast agent based on paramagnetic liposomes. Magnetic Resonance in Chemistry, 41, 585-588.
48. Louie, A.Y., Hüber, M.M., Ahrens, E.T., et al. (2000) In vivo visualization of gene expression using magnetic resonance imaging. Nature Biotechnology, 18, 321-325.
49. Moats, R.A., Fraser, S.E., and Meade, T.J. (1997)A"smart''magnetic resonance imaging agent that reports on specific enzymatic activity. Angewandte Chemie International Edition, 36, 726-728.
50. Duimstra, J.A., Femia, F.J., and Meade, T.J. (2005) A gadolinium chelate for detection of β-glucuronidase: a self-immolative approach. Journal of the American Chemical Society, 127, 12847-12855.
51. Hovland, R., Gløgård, C., Aasen, A.J., and Klaveness, J. (2001) Gadolinium DO3A derivatives mimicking phospholipids; preparation and in vitro evaluation as pH responsive MRI contrast agents. Journal of the Chemical Society, Perkin Transactions 2, 929-933.
52. Lowe, M.P., Parker, D., Reany, O., et al. (2001) pH-dependent modulation of relaxivity and luminescence in macrocyclic gadolinium and europium complexes based on reversible intramolecular sulfonamide ligation. Journal of the American Chemical Society, 123, 7601-7609.
53. Woods, M., Kiefer, G.E., Bott, S., et al. (2004) Synthesis, relaxometric and photophysical properties of a new pH-responsive MRI contrast agent: the effect of other ligating groups on dissociation of a p-nitrophenolic pendant arm. Journal of the American Chemical Society, 126, 9248-9256.
54. Woods, M., Zhang, S., Ebron, V.H., and Sherry, A.D. (2003) pH-sensitive modulation of the second hydration sphere in lanthanide(III) tetraamide-DOTA complexes: a novel approach to smart MR contrast media. Chemistry-A European Journal, 9, 4634-4640.
55. Zhang, S., Wu, K., and Sherry, A.D. (1999) A novel pH-sensitive MRI contrast agent. Angewandte Chemie International Edition, 38, 3192-3194.
56. Kálmán, F.K.,Woods,M., Caravan, P., et al. (2007) Potentiometric and relaxometric properties of a gadoliniumbased MRI contrast agent for sensing tissue pH. Inorganic Chemistry, 46, 5260-5270.
57. Raghunand, N., Howison, C., Sherry, A.D., et al. (2003) Renal and systemic pH imaging by contrast-enhanced MRI. Magnetic Resonance in Medicine, 49, 249-257.
58. Garcia-Martin, M.L., Martinez, G.V., Raghunand, N., et al. (2006) High resolution pHe imaging of rat glioma using pH-dependent relaxivity. Magnetic Resonance in Medicine, 55, 309-315.
59. Zhang, S., Merritt, M., Woessner, D.E., et al. (2003) PARACEST agents: modulating MRI contrast via water proton exchange. Accounts of Chemical Research, 36, 783-790.
60. Ward, K.M., Aletras, A.H., and Balaban, R.S. (2000) A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). Journal of Magnetic Resonance, 143, 79-87.
61. Ward, K.M. and Balaban, R.S. (2000) Determination of pH using water protons and chemical exchange dependent saturation transfer (CEST). Magnetic Resonance in Medicine, 44, 799-802.
62. 3+-DOTAM-glycine (Gly)-phenylalanine (Phe). Magnetic Resonance in Medicine, 59, 374-381.
63. Peter, T.J. (1996) All About Albumin: Biochemistry, Genetics, and Medical Applications, Academic Press, San Diego.
64. Lauffer, R.B. (1991) Targeted relaxation enhancement agents for MRI. Magnetic Resonance in Medicine, 22, 339-342.
65. Dwek, R.A. (1973) Nuclear Magnetic Resonance in Biochemistry: Application to Enzyme Systems, Clarendon Press, Oxford.
66. Jenkins, B.G., Armstrong, E., and Lauffer, R.B. (1991) Site-specific water proton relaxation enhancement of iron(III) chelates noncovalently bound to human serum albumin. Magnetic Resonance in Medicine, 17, 164-178.
67. Aime, S., Botta, M., Fasano, M., et al. (1996) Gd(III) complexes as contrast agents for magnetic resonance imaging: a proton relaxation enhancement study of the interaction with human serum albumin. Journal of Biological Inorganic Chemistry, 1, 312-319.
68. 17O NMR relaxometric investigations on two gadolinium(III) DTPA-like chelates endowed with high binding affinity to human serum albumin. Journal of Biological Inorganic Chemistry, 4, 766-774.
69. Botta, M., Quici, S., Pozzi, G., et al. (2004) NMR relaxometric study of new GdIII macrocyclic complexes and their interaction with human serum albumin. Organic and Biomolecular Chemistry, 2, 570-577.
70. Aime, S., Gianolio, E., Longo, D., et al. (2005) New insights for pursuing high relaxivity MRI agents from modelling the binding interaction of GdIII chelates to HAS. ChemBioChem., 6, 818-820.
71. Aime, S., Gianolio, E., Terreno, E., et al. (2000) Ternary Gd(III)L-HSA adducts: evidence for the replacement of inner-sphere water molecules by coordinating groups of the protein. Implications for the design of contrast agents for MRI. Journal of Biological Inorganic Chemistry, 5, 488-497.
72. Caravan, P., Cloutier, N.J., Greenfield, M.T., et al. (2002) The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. Journal of the American Chemical Society, 124, 3152-3162.
73. Tyeklár, Z., Dunham, S.U.,Midelfort, K., et al. (2007) Structural, kinetic, and thermodynamic characterization of the interconverting isomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorganic Chemistry, 46, 6621-6631.
74. Caravan, P., Parigi, G., Chasse, J.M., et al. (2007) Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorganic Chemistry, 46, 6632-6639.
75. Muller, R.N., Radüchel, B., Laurent, S., et al. (1999) Physicochemical characterization of MS-325, a new gadolinium complex, by multinuclear relaxometry. European Journal of Inorganic Chemistry, 1949-1955.
76. Zech, S.G., Eldredge, H.B., Lowe, M.P., and Caravan, P. (2007) Protein binding to lanthanide(III) complexes can reduce the water exchange rate at the lanthanide. Inorganic Chemistry, 46, 3576-3584.
77. Li, X., Zhang, S., Zhao, P., Kovacs, Z., and Sherry, A.D. (2001) Synthesis and NMR studies of new DOTPlike lanthanide(III) complexes containing a hydrophobic substituent on one phosphonate side arm. Inorganic Chemistry, 40, 6572-6579.
78. 3+ complex of a fatty acid analogue of DOTP binds to multiple albumin sites with variable water relaxivities. Inorganic Chemistry, 40, 6580-6587.
79. Anelli, P.L., Bertini, I., Fragai, M., et al. (2000) Sulfonamide-functionalized gadolinium DTPA complexes as possible contrast agents for MRI: a relaxometric investigation. European Journal of Inorganic Chemistry, 625-630.
80. 3+. Magnetic resonance imaging contrast agents with a prominent receptor-induced magnetization enhancement. Angewandte Chemie International Edition, 40, 2903-2906.
81. Chen, J.W., Pham,W.,Weissleder, R., and Bogdanov, A. Jr (2004) Human myeloperoxidase: a potential target for molecular MR imaging in atherosclerosis. Magnetic Resonance in Medicine, 52, 1021-1028.
82. Bogdanov, A. Jr, Matuszewski, L., Bremer, C., et al. (2002) Oligomerization of paramagnetic substrates result in signal amplification and can be used for MR imaging of molecular targets. Molecular Imaging, 1, 16-23.
83. Lee, J., Zylka, M.J., Anderson, D.J., et al. (2005) A steroid-conjugated contrast agent for magnetic resonance imaging of cell signaling. Journal of the American Chemical Society, 127, 13164-13166.
84. Lee, J., Burdette, J.E., MacRenaris, K.W., et al. (2007) Rational design, synthesis, and biological evaluation of progesterone-modified MRI contrast agents. Chemistry and Biology, 14, 824-834.
85. Zhang, Z., Greenfield, M.T., Spiller, M., et al. (2005) Multilocus binding increases the relaxivity of proteinbound MRI contrast agents. Angewandte Chemie International Edition, 44, 6766-6769.
86. Lin, S.P. and Brown, J.J. (2007) MR contrast agents: physical and pharmacologic basics. Journal of Magnetic Resonance Imaging, 25, 884-899.
87. Evans, C.H. (1990) Biochemistry of the Lanthanides, Plenum Press, New York.
88. Kasokat, T. and Urich, K. (1992) Quantification of dechelation of gadopentetate dimeglumine in rats. Arzneimittelforschung, 42, 869-876.
89. Idée, J.M., Port, M., Raynal, I., et al. (2006) Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundamental and Clinical Pharmacology, 20, 563-576.
90. Tweedle, M.F.,Wedeking, P., and Kumar, K. (1995) Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Investigative Radiology, 30, 372-380.
91. White, G.W., Gibby, W.A., and Tweedle, M.F. (2006) Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Investigative Radiology, 41, 272-278.
92. Cowper, S.E., Robin, H.S., Steinberg, S.M., et al. (2000) Scleromyxoedema-like cutaneous diseases in renaldialysis patients. Lancet, 356, 1000-1001.
93. Joffe, P., Thomsen, H.S., and Meusel, M. (1998) Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Academic Radiology, 5, 491-502.
94. Wiginton, C.D., Kelly, B., Oto, A., et al. (2008) Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. American Journal of Roentgenology, 190, 1060-1068.
95. Burtea, C., Laurent, S., Elst, L.V., and Muller, R.N. (2008) Contrast agents: magnetic resonance. Handbook of Experimental Pharmacology, 185, 135-165.
96. Döhr, O., Hofmeister, R., Treher, M., and Schweinfurth, H. (2007) Preclinical safety evaluation of Gd-EOBDTPA (Primovist). Investigative Radiology, 42, 830-841.
97. Steger-Hartmann, T., Graham, P.B., Müller, S., and Schweinfurth, H. (2006) Preclinical safety assessment of vasovist (Gadofosveset trisodium), a new magnetic resonance imaging contrast agent for angiography. Investigative Radiology, 41, 449-459.
98. Tombach, B. and Heindel, W. (2002) Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol. European Radiology, 12, 1550-1556.
99. Zhang, Z., Nair, S.A., and McMurry, T.J. (2005) Gadolinium meets medicinal chemistry: MRI contrast agent development. Current Medicinal Chemistry, 12, 751-778.
100. Li, D., Zheng, J., Bae, K.T., et al. (1998) Contrast-enhanced magnetic resonance imaging of the coronary arteries. Investigative Radiology, 33, 578-586.
101. Mühler, A. (1998) The future of contrast-enhanced magnetic resonance angiography: are blood pool agents needed? Investigative Radiology, 33, 709-714.
102. Caravan, P., Comuzzi, C., Crooks,W., et al. (2001) Thermodynamic stability and kinetic inertness of MS-325, a new blood pool agent for magnetic resonance imaging. Inorganic Chemistry, 40, 2170-2176.
103. Lauffer, R.B., Parmelee, D.J., Ouellet, H.S., et al. (1996) MS-325: a small-molecule vascular imaging agent for magnetic resonance imaging. Academic Radiology, 3, S356-S358.
104. Lauffer, R.B., Parmelee, D., Dunham, S.U., et al. (1998) MS-325: albumin-targeted contrast agent for MR angiography. Radiology, 207, 529-538.
105. Parmelee, D.J.,Walovitch, R.C., Ouellet, H.S., and Lauffer, R.B. (1997) Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging. Investigative Radiology, 32, 741-747.
106. Eldredge, H.B., Spiller, M., Chasse, J.M., et al. (2006) Species dependence on plasma protein binding and relaxivity of the gadolinium-based MRI contrast agent MS-325. Investigative Radiology, 41, 229-243.
107. Grist, T.M., Korosec, F.R., Peters, D.C., et al. (1998) Steady-state and dynamicMR angiography with MS-325: initial experience in humans. Radiology, 207, 539-544.
108. Bluemke, D.A., Stillman, A.E., Bis, K.G., et al. (2001) Carotid MR angiography: phase II study of safety and efficacy for MS-325. Radiology, 219, 114-122.
109. Kelle, S., Thouet, T., Tangcharoen, T., et al. (2007) Whole-heart coronary magnetic resonance angiography with MS-325 (gadofosveset). Medical Science Monitor, 13, CR469-CR474.
110. Chiribiri, A., Kelle, S., Götze, S., et al. (2008) Visualization of the cardiac venous system using cardiac magnetic resonance. American Journal of Cardiology, 101, 407-412.
111. Kroft, L.J.M. and de Roos, A. (1999) Blood pool contrast agents for cardiovascular MR imaging. Journal of Magnetic Resonance Imaging, 10, 395-403.
112. Ruehm, S.G., Christina, H., Violas, X., et al. (2002) MR angiography with a new rapid-clearance blood pool agent: initial experience in rabbits. Magnetic Resonance in Medicine, 48, 844-851.
113. Dewey, M., Kaufels, N., Laule, M., et al. (2004) Assessment of myocardial infarction in pigs using a rapid clearance blood pool contrast medium. Magnetic Resonance in Medicine, 51, 703-709.
114. Port, M., Corot, C., Violas, X., et al. (2005) How to compare the efficiency of albumin-bound and nonalbumin-bound contrast agents in vivo the concept of dynamic relaxivity. Investigative Radiology, 40, 565-573.
115. Kirchin, M.A., Pirovano, G.P., and Spinazzi, A. (1998) Gadobenate dimeglumine (Gd-BOPTA): an overview. Investigative Radiology, 33, 798-809.
116. Clement, O., Mühler, A., Vexler, V., et al. (1992) Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic-resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats. Investigative Radiology, 27, 612-619.
117. Katzberg, R.W. and Schuhmann-Giampieri, G. (1993) Liver contrast media for magnetic resonance imaging interrelations between pharmacokinetics and imaging. Investigative Radiology, 8, 753-761.
118. Schuhmann-Giampieri, G., Frenzel, T., and Schmitt-Willich, H. (1993) Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. Arzneimittelforschung, 43, 927-931.
119. Spinazzi, A., Lorusso, V., Pirovano, G., and Kirchin, M. (1999) Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Academic Radiology, 6, 282-291.
120. Hamm, B., Staks, T., Mühler, A., et al. (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology, 195, 785-792.
121. Spinazzi, A., Lorusso, V., Pirovano, G., et al. (1998) MultiHance clinical pharmacology: biodistribution and MR enhancement of the liver. Academic Radiology, 5, S86-S89.
122. Schuhmann-Giampieri, G., Schmitt-Willich, H., Press, W.R., et al. (1992) Preclinical evaluation of Gd-EOBDTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology, 183, 59-64.
123. Karabulut, N. and Elmas, N. (2006) Contrast agents used in MR imaging of the liver. Diagnostic and Interventional Radiology, 12, 22-30.
124. Reimer, P., Schneider, G., and Schima, W. (2004) Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. European Radiology, 14, 559-578.
125. Cavagna, F.M., Maggioni, F., Castelli, P.M., et al. (1997) Gadolinium chelates with weak binding to serum proteins-a new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Investigative Radiology, 32, 780-796.
126. Reimer, P., Rummeny, E.J., Shamsi, K., et al. (1996) Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology, 199, 177-183.
127. Balci, N.C. and Semelka, R.C. (2005) Contrast agents forMR imaging of the liver. Radiologic Clinics of North America, 43, 887-898.
128. Petersein, J., Spinazzi, A., Giovagnoni, A., et al. (2000) Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging-A multicenter phase III clinical study. Radiology, 215, 727-736.
129. Huppertz, A., Balzer, T., Blakeborough, A., et al. (2004) Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology, 230, 266-275.
130. Kim, Y.K., Lee, J.M., and Kim, C.S. (2004) Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. European Radiology, 14, 5-13.
131. Planchamp, C., Gex-Fabry, M., Becker, C.D., and Pastor, C.M. (2007) Model-based analysis of Gd-BOPTA-induced MR signal intensity changes in cirrhotic rat livers. Investigative Radiology, 42, 513-521.
132. Yoo, H.J., Lee, J.M., Lee, M.W., et al. (2008) Hepatocellular carcinoma in cirrhotic liver: double-contrastenhanced, high-resolution 3.0T-MRimagingwith pathologic correlation. InvestigativeRadiology, 43, 538-546.
133. Folkman, J. (1996) New perspectives in clinical oncology from angiogenesis research. European Journal of Cancer, 32A, 2534-2539.
134. Hicklin, D. and Ellis, L.M. (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology, 23, 1011-1027.
135. Dvorak, H.F., Brown, L.F.,Detmar, M., andDvorak,A.M. (1995)Vascular permeability factornascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. American Journal of Pathology, 146, 1029-1039.
136. Brooks, P.C., Clark, R.A., and Cheresh, D.A. (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science, 264, 569-571.
137. Hynes, R.O. (2002) Integrins: bidirectional, allosteric signaling machines. Cell, 110, 673-687.
138. Hood, J.D. and Cheresh, D.A. (2002) Role of integrins in cell invasion and migration. Nature Reviews Cancer, 2, 91-100.
139. Knopp, M.V., Giesel, F.L.,Marcos, H., et al. (2001) Dynamic contrast-enhanced magnetic resonance imaging in oncology. Topics in Magnetic Resonance Imaging, 12, 301-308.
140. Marzola, P., Degrassei, A., Calderan, L., et al. (2004) In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clinical Cancer Research, 10, 739-750.
141. Medved, M., Karczmar, G., Yang, C., et al. (2004) Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: variability and changes in tumor tissue over time. Journal of Magnetic Resonance Imaging, 20, 122-128.
142. Liu, G., Rugo, H.S., Wilding, G., et al. (2005) Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. Journal of Clinical Oncology, 23, 5464-5473.
143. O'Connor, J.P.B., Jackson, A., Parker, G.J.M., and Jayson, G.C. (2007) DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. British Journal of Cancer, 96, 189-195.
144. Longo, R. and Gasparini, G. (2008) Anti-VEGF therapy: the search for clinical biomarkers. Expert Review of Molecular Diagnostics, 8, 301-314.
145. Hoffmann, U., Brix, G., Knopp, M.V., et al. (1995) Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magnetic Resonance in Medicine, 33, 506-514.
146. Buckley, D.L., Drew, P.J.,Mussurakis, S., et al. (1997) Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI. Journal of Magnetic Resonance Imaging, 7, 461-464.
147. Mussurakis, S., Buckley, D.L., and Horsman, A. (1997) Dynamic MR imaging of invasive breast cancer: correlation with tumour grade and other histological factors. British Journal of Radiology, 70, 446-451.
148. Buadu, L.D., Murakami, J., Murayama, S., et al. (1996) Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology, 200, 639-649.
149. Buadu, L.D., Murakami, J., Murayama, S., et al. (1997) Patterns of peripheral enhancement in breast masses: correlation of findings on contrast medium enhanced MRI with histologic features and tumor angiogenesis. Journal of Computer Assisted Tomography, 21, 421-430.
150. Matsubayashi, R., Matsuo, Y., Edakuni, G., et al. (2000) Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. Radiology, 217, 841-848.
151. Mahfouz, A.E., Sherif, H., Saad, A., et al. (2001) Gadolinium-enhanced MR angiography of the breast: is breast cancer associated with ipsilateral higher vascularity? European Radiology, 11, 965-969.
152. Pediconi, F., Catalano, C., Occhiato, R., et al. (2005) Breast lesion detection and characterization at contrastenhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine. Radiology, 237, 45-56.
153. Knopp, M.V., Bourne, M.W., Sardanelli, F., et al. (2003) Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine. American Journal of Roentgenology, 181, 663-676.
154. Sardanelli, F., Iozzelli, A., Fausto, A., et al. (2005) Gadobenate dimeglumine-enhanced MR imaging breast vascular maps: association between invasive cancer and ipsilateral increased vascularity. Radiology, 235, 791-797.
155. Sardanelli, F., Fausto, A., Menicagli, L., and Esseridou, A. (2007) Breast vascular mapping obtained with contrast-enhanced MR imaging: implications for cancer diagnosis, treatment, and risk stratification. European Radiology Supplements, 17, F48-F51.
156. Dafni, H., Kim, S.J., Bankson, J.A., et al. (2008) Macromolecular dynamic contrast-enhanced (DCE)-MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti-plateletderived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial growth factor receptor (VEGFR) Activation. Magnetic Resonance in Medicine, 60, 822-833.
157. 3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA. Cardiovascular Research, 78, 148-157.
158. Towner, R.A., Smith, N., Doblas, S., et al. (2008) In vivo detection of c-met expression in a rat C6 glioma model. Journal of Cellular and Molecular Medicine, 12, 174-186.
159. Kraitchman, D.L. and Bulte, J.W.M. (2008) Imaging of stem cells using MRI. Basic Research in Cardiology, 103, 105-113.